Key result
2D-SWE accurately detects significant MASLD fibrosis, with a 6.6 kPa cut-off reliably ruling it out.
Why the study?
Does 2D-SWE accurately rule out significant fibrosis in adults with MASLD compared to liver biopsy?
Meta-Analysis (n=3,171)
Does 2D-SWE accurately rule out significant fibrosis in adults with MASLD compared to liver biopsy?
A 2D-SWE liver stiffness cut-off of 6.6 kPa can reliably rule out significant fibrosis in patients with MASLD, facilitating broader screening.
Answers are grounded in this paper and cite their sources.
Moderate sensitivity supports cautious non-invasive fibrosis assessment in practice; extends pooled diagnostic data but leaves comparative validation open.
BACKGROUND & AIMS Two-dimensional shear-wave elastography (2D-SWE) is a practical method for assessing liver fibrosis. However, an optimal cut-off value to rule out significant fibrosis (≥F2) in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. This study aimed to determine the evidence-based rule-out cut-off through diagnostic meta-analysis. METHODS A systematic review was of MEDLINE, EMBASE, and Cochrane CENTRAL was performed through December 2025 for studies evaluating 2D-SWE with liver biopsy as the reference standard. Pooled sensitivity, specificity, and summary area under the receiver operating characteristic curve (sAUC) were estimated. The rule-out cut-off was defined as the highest threshold achieving pooled sensitivity ≥80%. External validation was performed using an independent clinical cohort. RESULTS Twenty-two studies involving 3,171 adults with biopsy-proven MASLD were analyzed. The sAUC was 0.84 (95% confidence interval (CI), 0.81-0.87), with pooled sensitivity 79.6% and specificity 76.0%. The rule-out cut-off of 6.6 kPa (95% CI, 5.4-8.2) achieved sensitivity 80.0% and specificity 70.7%. At this threshold, negative predictive value exceeded 95% at prevalences of 5% and 10%. Diagnostic performance was generally preserved across subgroups, but was modestly attenuated in populations with greater metabolic burden and in studies using Supersonic ultrasound platforms. External validation (n=163) demonstrated consistent sensitivity (0.86) and specificity (0.68). CONCLUSIONS 2D-SWE demonstrated good diagnostic accuracy for significant fibrosis in MASLD. A liver stiffness of 6.6 kPa can reliably rule out significant fibrosis. As 2D-SWE can be integrated into conventional ultrasound systems, it may facilitate broader implementation of fibrosis screening beyond specialized centers. [Clinical trial number: PROSPERO (International Prospective Register of Systematic Reviews), CRD42024616042].
No takes yet. Share an insight, caveat, or question.
Oh et al. (2026) conducted a meta-analysis in Metabolic dysfunction-associated steatotic liver disease (MASLD) (n=3,171). Two-dimensional shear-wave elastography (2D-SWE) vs. Liver biopsy was evaluated on Diagnostic accuracy (sAUC) for significant fibrosis (≥F2) (sAUC 0.84, 95% CI 0.81-0.87). Two-dimensional shear-wave elastography demonstrated good diagnostic accuracy for significant fibrosis in MASLD, with a 6.6 kPa cut-off reliably ruling out the condition.
Synapse has enriched 10 related papers. Consider them for comparative context: